Insider Transactions in Q1 2021 at Eidos Therapeutics, Inc. (EIDX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 26
2021
|
Uma Sinha Chief Scientific Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
303,525
-100.0%
|
-
|
|
Jan 26
2021
|
Cameron Turtle Chief Business Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
50,699
-100.0%
|
-
|
|
Jan 26
2021
|
Jonathan C Fox Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
380,467
-100.0%
|
-
|
|
Jan 26
2021
|
Bridge Bio Pharma, Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
14,428,836
+99.99%
|
-
|
|
Jan 13
2021
|
Uma Sinha Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-0.53%
|
$1,230,000
$123.89 P/Share
|
|
Jan 12
2021
|
Franco Valle Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
1,747
-100.0%
|
$218,375
$125.44 P/Share
|
|
Jan 12
2021
|
Franco Valle Senior Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
1,747
+50.0%
|
$12,229
$7.24 P/Share
|
|
Jan 11
2021
|
Franco Valle Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
1,500
-100.0%
|
$187,500
$125.61 P/Share
|
|
Jan 11
2021
|
Franco Valle Senior Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$10,500
$7.24 P/Share
|